Wire · opportunities
What Does Lantheus Holdings (LNTH) FDA Approval Mean For Its Alzheimer's Push?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 August 2026 · Fusion42 review
Lantheus Holdings received FDA approval for TAUKLARIFY, a tau PET imaging agent to enhance Alzheimer's disease diagnostics, expanding its molecular imaging portfolio focused on neurodegenerative disease. This approval strengthens Lantheus' position in the Alzheimer's diagnostic market amid competition from GE HealthCare and Eli Lilly.
This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 14 Aug 2026 and 15 Aug 2026.
◆ ◆ The Wire takeaway
Your Alzheimer’s diagnostic options just broadened with Lantheus’ FDA-approved tau imaging. You can move to explore partnerships or product development that leverage early diagnosis tools in neurodegenerative care.
◆ Coverage
4 sources · first reported 14 Aug 2026 · latest 15 Aug 2026
◆ Related on Wire
◆ Topics